INSM Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of -2.24%. Insmed, Inc.'s return on equity of -192.35% beat Biogen, Inc.'s return on equity of 7.36%.

Insmed, Inc. has a consensus price target of $213.11, signalling upside risk potential of 33.15%. On the other hand Biogen, Inc. has an analysts' consensus of $205.52 which suggests that it could grow by 7%. Given that Insmed, Inc. has higher upside potential than Biogen, Inc., analysts believe Insmed, Inc. is more attractive than Biogen, Inc..

Insmed, Inc. has a beta of 1.105, which suggesting that the stock is 10.538% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.160, suggesting its less volatile than the S&P 500 by 84.033%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are smaller than Biogen, Inc. quarterly revenues of $2.2B. Insmed, Inc.'s net income of -$328.5M is lower than Biogen, Inc.'s net income of -$48.9M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 21.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 52.80x versus 2.96x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of 49.9%. Insmed, Inc.'s return on equity of -192.35% beat CorMedix, Inc.'s return on equity of 95.25%.

Insmed, Inc. has a consensus price target of $213.11, signalling upside risk potential of 33.15%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 109.85%. Given that CorMedix, Inc. has higher upside potential than Insmed, Inc., analysts believe CorMedix, Inc. is more attractive than Insmed, Inc..

Insmed, Inc. has a beta of 1.105, which suggesting that the stock is 10.538% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Insmed, Inc.'s net income of -$328.5M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 52.80x versus 2.38x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of 18.06%. Insmed, Inc.'s return on equity of -192.35% beat Merck & Co., Inc.'s return on equity of 39.63%.

Insmed, Inc. has a consensus price target of $213.11, signalling upside risk potential of 33.15%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.48%. Given that Insmed, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Insmed, Inc. is more attractive than Merck & Co., Inc..

Insmed, Inc. has a beta of 1.105, which suggesting that the stock is 10.538% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.69% to investors and pays a quarterly dividend of $0.85 per share. Insmed, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Insmed, Inc. quarterly revenues are $263.8M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Insmed, Inc.'s net income of -$328.5M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 52.80x versus 4.70x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of -9.34%. Insmed, Inc.'s return on equity of -192.35% beat Pfizer Inc.'s return on equity of 10.84%.

Insmed, Inc. has a consensus price target of $213.11, signalling upside risk potential of 33.15%. On the other hand Pfizer Inc. has an analysts' consensus of $28.56 which suggests that it could grow by 6.89%. Given that Insmed, Inc. has higher upside potential than Pfizer Inc., analysts believe Insmed, Inc. is more attractive than Pfizer Inc..

Insmed, Inc. has a beta of 1.105, which suggesting that the stock is 10.538% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.4% to investors and pays a quarterly dividend of $0.43 per share. Insmed, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Insmed, Inc.'s net income of -$328.5M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 52.80x versus 2.45x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.